<DOC>
	<DOCNO>NCT02164578</DOCNO>
	<brief_summary>Study investigate microvascular antiinflammatory effect Rivaroxaban compare low dose aspirin type 2 diabetic patient . Especially patient cardiovascular disease subclinical inflammation focus interest .</brief_summary>
	<brief_title>Microvascular Antiinflammatory Effects Rivaroxaban Compared Aspirin Type-2 Diabetic Patients With Cardiovascular Disease</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>type 2 diabetes duration 2 20 year document atherosclerotic CVD : major cardiovascular event medical history coronary angiography show coronary artery stenosis &gt; 50 % carotid ultrasound show IMT &gt; 1 mm plaque carotid artery leave ventricular hypertrophy macroalbuminuria absence renal disease increase hsCRP ( &gt; 2 mg/l &lt; 10 mg/l ) and/or increase PAI 1 ( &gt; 15 ng/ml ) stable treatment statin ( tolerate ) age 40 75 year CV event need oral anticoagulation dual platelet inhibitor therapy acute coronary syndrome &lt; 12 month study entry sustain uncontrolled hypertension : systolic bp &gt; 180 mmHg diastolic bp &gt; 100 mmHg hypersensitivity active substance active clinically significant bleed significant risk major bleed concomitant treatment ACS antiplatelet therapy patient prior stroke transient ischaemic attack ( TIA ) hepatic disease associate coagulopathy clinically relevant bleeding risk chronic renal failure eGFR &lt; 15 ml/min ( MDRD formula ) Pregnant breastfeed woman woman without adequate method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>